{"disease":{"id":"ovarian-adenocarcinoma","name":"ovarian adenocarcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00488878","title":"Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00951496","title":"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1560,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04152499","title":"Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Klus Pharma Inc.","has_results":false},{"nct_id":"NCT00108745","title":"Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":1157,"lead_sponsor_name":"GOG Foundation","has_results":true},{"nct_id":"NCT00719303","title":"Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":1070,"lead_sponsor_name":"Gynecologic Oncology Group","has_results":false},{"nct_id":"NCT00565851","title":"Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1052,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04389632","title":"A Study of Sigvotatug Vedotin in Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1006,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT03170960","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":914,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT06580314","title":"Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":880,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT05973487","title":"A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":840,"lead_sponsor_name":"TScan Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT01167712","title":"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":692,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04498117","title":"Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":615,"lead_sponsor_name":"CanariaBio Inc.","has_results":false},{"nct_id":"NCT02502266","title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":582,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04575935","title":"Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":580,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02446600","title":"Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":579,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05797168","title":"Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":506,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03150121","title":"Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage","phase":"NA","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Sheba Medical Center","has_results":false},{"nct_id":"NCT04095364","title":"Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":450,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT02839707","title":"Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":444,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00989651","title":"Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":431,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05470920","title":"Genetic Testing Decision Aid","phase":"NA","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT02611024","title":"Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":316,"lead_sponsor_name":"PharmaMar","has_results":false},{"nct_id":"NCT02101788","title":"Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":260,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04794322","title":"Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT06792435","title":"XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Evopoint Biosciences Inc.","has_results":false},{"nct_id":"NCT05796973","title":"Measuring Oncological Value of Exercise and Statin","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Tampere University Hospital","has_results":false},{"nct_id":"NCT07100288","title":"Anatomopathological Analysis of the Infundibulopelvic Ligament in Patients With Ovarian Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Complejo Hospitalario Universitario Insular Materno Infantil","has_results":false},{"nct_id":"NCT05554367","title":"Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":199,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04802876","title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":184,"lead_sponsor_name":"SOLTI Breast Cancer Research Group","has_results":false},{"nct_id":"NCT05329532","title":"Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"Scancell Ltd","has_results":false},{"nct_id":"NCT04055038","title":"Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":164,"lead_sponsor_name":"Blokhin's Russian Cancer Research Center","has_results":false},{"nct_id":"NCT02208375","title":"mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":159,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01116648","title":"Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":155,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03593681","title":"Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Boston Scientific Corporation","has_results":true},{"nct_id":"NCT04248231","title":"CINSARC Genomic Signature as Predictor of Resectability of Ovarian Adenocarcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Institut Claudius Regaud","has_results":false},{"nct_id":"NCT02713386","title":"Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"NRG Oncology","has_results":true},{"nct_id":"NCT04851119","title":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":147,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT06517485","title":"First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"Mersana Therapeutics","has_results":false},{"nct_id":"NCT03748186","title":"Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":136,"lead_sponsor_name":"Sutro Biopharma, Inc.","has_results":false},{"nct_id":"NCT03648489","title":"Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT03329950","title":"A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":132,"lead_sponsor_name":"Celldex Therapeutics","has_results":false},{"nct_id":"NCT05601700","title":"Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Ente Ospedaliero Ospedali Galliera","has_results":false},{"nct_id":"NCT02101775","title":"Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":124,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04739800","title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03983954","title":"Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"NeoTX Therapeutics Ltd.","has_results":false},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}